TB diagnostic test set for India green light

BIOTECH company Epistem is on the verge of receiving approval for its first molecular diagnostic test for Tuberculosis from the Indian government.

The Manchester-based firm is pinning its hopes on the launch of the Genedrive kit after reporting a £700,000 fall in revenues recently.

Preparations for the launch of Genedrive on the Indian sub-continent underpinned increased levels of investment, giving rise to an after-tax loss of £1.9m.

The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for Tuberculosis into their disease testing programs.

The Genedrive platform and its first Tuberculosis has been under development undergoing clinical studies in countries across the world.

Epistem has now been notified that the director general of health services, ministry of health and family welfare of the Indian government will publish an approval letter for the import of the Genedrive diagnostic kit.